RTW Investments LP Has $212.24 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

RTW Investments LP grew its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,498,545 shares of the company's stock after buying an additional 72,433 shares during the quarter. Protagonist Therapeutics makes up 3.2% of RTW Investments LP's portfolio, making the stock its 10th largest position. RTW Investments LP owned 9.23% of Protagonist Therapeutics worth $212,244,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new stake in Protagonist Therapeutics during the 4th quarter worth $38,000. Covestor Ltd raised its position in Protagonist Therapeutics by 5,200.0% in the 4th quarter. Covestor Ltd now owns 1,643 shares of the company's stock valued at $63,000 after buying an additional 1,612 shares during the last quarter. KBC Group NV lifted its position in shares of Protagonist Therapeutics by 54.4% in the fourth quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after purchasing an additional 737 shares in the last quarter. New Vernon Capital Holdings II LLC bought a new stake in Protagonist Therapeutics during the 4th quarter worth about $118,000. Finally, Nisa Investment Advisors LLC boosted its position in Protagonist Therapeutics by 10.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after purchasing an additional 295 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PTGX. JMP Securities reiterated a "market outperform" rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research note on Friday, February 7th. The Goldman Sachs Group dropped their price target on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a research report on Monday, February 24th. Wedbush reiterated an "outperform" rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, March 28th. Truist Financial raised their target price on Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $65.44.

Protagonist Therapeutics Trading Down 2.7%

NASDAQ:PTGX traded down $1.26 during trading hours on Wednesday, hitting $45.35. 210,958 shares of the company were exchanged, compared to its average volume of 874,633. The stock has a market capitalization of $2.81 billion, a price-to-earnings ratio of 17.05 and a beta of 2.65. The company has a fifty day simple moving average of $46.36 and a 200 day simple moving average of $42.59. Protagonist Therapeutics, Inc. has a one year low of $27.00 and a one year high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.31. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The company had revenue of $28.32 million during the quarter, compared to analysts' expectations of $30.44 million. Equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Protagonist Therapeutics

In other news, CFO Asif Ali sold 24,903 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the transaction, the chief financial officer now directly owns 62,821 shares of the company's stock, valued at $3,689,477.33. This represents a 28.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Arturo Md Molina sold 30,514 shares of the firm's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the completion of the transaction, the insider now directly owns 83,892 shares in the company, valued at $4,676,140.08. This trade represents a 26.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,173 shares of company stock valued at $3,461,180. 4.90% of the stock is currently owned by company insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.